Everything below concerns retatrutide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Several new methods for DNA sequencing were developed in the mid to late 1990s and were implemented in commercial DNA sequencers by 2000. Together these were called the "next-generation" or "second-generation" sequencing (NGS) methods, in order to distinguish them from the earlier methods, including Sanger sequencing. In contrast to the first generation of sequencing, NGS technology is typically characterized by being highly scalable, allowing the entire genome to be sequenced at once. Usually, this is accomplished by fragmenting the genome into small pieces, randomly sampling for a fragment, and sequencing it using one of a variety of technologies, such as those described below. An entire genome is possible because multiple fragments are sequenced at once (giving it the name "massively parallel" sequencing) in an automated process. NGS technology has tremendously empowered researchers to look for insights into health, anthropologists to investigate human origins, and is catalyzing the "Personalized Medicine" movement. However, it has also opened the door to more room for error. There are many software tools to carry out the computational analysis of NGS data, often compiled at online platforms such as CSI NGS Portal, each with its own algorithm. Even the parameters within one software package can change the outcome of the analysis. In addition, the large quantities of data produced by DNA sequencing have also required development of new methods and programs for sequence analysis.
==== Polymerases ==== Polymerases are enzymes that synthesize polynucleotide chains from nucleoside triphosphates. The sequence of their products is created based on existing polynucleotide chains—which are called templates. These enzymes function by repeatedly adding a nucleotide to the 3′ hydroxyl group at the end of the growing polynucleotide chain. As a consequence, all polymerases work in a 5′ to 3′ direction. In the active site of these enzymes, the incoming nucleoside triphosphate base-pairs to the template: this allows polymerases to accurately synthesize the complementary strand of their template. Polymerases are classified according to the type of template that they use. In DNA replication, DNA-dependent DNA polymerases make copies of DNA polynucleotide chains. To preserve biological information, it is essential that the sequence of bases in each copy are precisely complementary to the sequence of bases in the template strand. Many DNA polymerases have a proofreading activity. Here, the polymerase recognizes the occasional mistakes in the synthesis reaction by the lack of base pairing between the mismatched nucleotides. If a mismatch is detected, a 3′ to 5′ exonuclease activity is activated and the incorrect base removed. In most organisms, DNA polymerases function in a large complex called the replisome that contains multiple accessory subunits, such as the DNA clamp or helicases. RNA-dependent DNA polymerases are a specialized class of polymerases that copy the sequence of an RNA strand into DNA.
Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non-food (industrial) uses of crops and other products (e.g., biodegradable plastics, vegetable oil, biofuels), and environmental uses. For example, one application of biotechnology is the directed use of microorganisms for the manufacture of organic products (examples include beer and milk products). Another example is using naturally present bacteria by the mining industry in bioleaching. Biotechnology is also used to recycle, treat waste, clean up sites contaminated by industrial activities (bioremediation), and also to produce biological weapons. A series of derived terms have been coined to identify several branches of biotechnology, for example:
== Discovery == In 1948, Sutherland and De Duve identified a gastrointestinal glucagon-like material in gastric mucosa, the term "enteroglucagon" was used to describe this material that shared a similar immunoreactivity with glucagon. A half-century later, Brubaker and Drucker studied proglucagon gene expression, they discovered the function of enteroglucagon is related to the growth of intestinal epithelium.
Sources: en.wikipedia.org
1883. A Treatise on the Motion of Vortex Rings: An essay to which the Adams Prize was adjudged in 1882, in the University of Cambridge. London: Macmillan and Co., pp. 146. Recent reprint: ISBN 0-543-95696-2. 1888. Applications of Dynamics to Physics and Chemistry. London: Macmillan and Co., pp. 326. Recent reprint: ISBN 1-4021-8397-6. 1893. Notes on recent researches in electricity and magnetism: intended as a sequel to Professor Clerk-Maxwell's 'Treatise on Electricity and Magnetism'. Oxford University Press, pp. xvi & 578. 1991, Cornell University Monograph: ISBN 1-4297-4053-1. Thomson, Joseph John (1893). Notes on recent researches in electricity and magnetism. Oxford: Clarendon Press. Thomson, Joseph John (1900). Discharge of electricity through gases (in German). Leipzig: Johann Ambrosius Barth. Thomson, Joseph John (1904). Electricity and matter (in English). Oxford : Clarendon Press. Thomson, Joseph John (1905). Electricity and matter (in Italian). Milano: Hoepli. Thomson, Joseph John (1908). Corpuscular theory of matter (in German). Braunschweig: Vieweg und Sohn. 1921 (1895). Elements of the Mathematical Theory of Electricity And Magnetism. London: Macmillan and Co. Scan of 1895 edition. A Text book of Physics in Five Volumes, co-authored with J.H. Poynting: (1) Properties of Matter, (2) Sound, (3) Heat, (4) Light, and (5) Electricity and Magnetism. Dated 1901 and later, and with revised later editions. Dahl, Per F. (1997). Flash of the Cathode Rays: A History of J J Thomson's Electron. Bristol and Philadelphia: Institute of Physics Publishing. ISBN 0-7503-0453-7.
== Contraindications == Dihydroergotamine is contraindicated with potent CYP3A4 inhibitors, like macrolide antibiotics. Contraindications for dihydroergotamine include: pregnancy, kidney failure or liver failure, coronary, cerebral, and peripheral vascular disease, hypersensitivity reactions, sepsis, and uncontrolled hypertension.
== Research == Butler is a heart failure expert, with research spanning prevention to advanced therapies, including cardiac transplantation and ventricular assist devices. He has published more than 1,500 peer-reviewed publications. He has led or participated in over 100 clinical trials, developed the Atlanta Cardiomyopathy Consortium, and helped establish the NIH-funded Heart Failure Network at Emory University. Butler is a senior consulting editor for the Journal of the American College of Cardiology associate editor for the European Heart Journal section editor for the Journal of the American College of Cardiology: Heart Failure guest editor for the European Journal of Heart Failure, and serves on the editorial board of Circulation. He has also peer-reviewed for journals, including the New England Journal of Medicine, Journal of the American Medical Association (JAMA), and Lancet.
=== Amphibians === Plethodontid salamanders and chameleons have evolved a harpoon-like tongue to catch insects. The Neotropical poison dart frog and the Mantella of Madagascar have independently developed similar mechanisms for obtaining alkaloids from a diet of mites and storing the toxic chemicals in skin glands. They have also independently evolved similar bright skin colors that warn predators of their toxicity (by the opposite of crypsis, namely aposematism). Caecilians are lissamphibians that secondarily lost their limbs, superficially resembling snakes and legless lizards. Oldest known tetrapods (semi-aquatic Ichthyostegalia) resembled giant salamanders (body plan, lifestyle), though they are considered to be only distantly related.
Librarian Ainsworth Rand Spofford, who directed the Library of Congress from 1865 to 1897, built broad bipartisan support to develop it as a national library and a legislative resource. He was aided by expansion of the federal government after the war and a favorable political climate. He began comprehensively collecting Americana and American literature, led the construction of a new building to house the library, and transformed the librarian of Congress position into one of strength and independence. Between 1865 and 1870, Congress appropriated funds for the construction of the Thomas Jefferson Building, placed all copyright registration and deposit activities under the library's control, and restored the international book exchange. The library also acquired the vast libraries of the Smithsonian and of historian Peter Force, strengthening its scientific and Americana collections significantly. By 1876, the Library of Congress had 300,000 volumes; it was tied with the Boston Public Library as the nation's largest library. It moved from the Capitol building to its new headquarters in 1897 with more than 840,000 volumes, 40 percent of which had been acquired through copyright deposit. A year before the library's relocation, the Joint Library Committee held hearings to assess the condition of the library and plan for its future growth and possible reorganization. Spofford and six experts sent by the American Library Association testified that the library should continue its expansion to become a true national library.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.